other material
confidence high
sentiment positive
materiality 0.70
Immunic reports phase 1b IMU-856 data: reduced villous height loss, improved symptoms, no safety issues
IMMUNIC, INC.
- Placebo group had 60.3 µm villous height reduction vs. 20.9 µm (80mg) and 22.5 µm (160mg) for IMU-856 (p=0.04) under gluten challenge.
- On first gluten challenge day, placebo symptom increases (nausea 0.8, pain 0.8, diarrhea 0.8) vs. pooled IMU-856 (0.4, 0.5, 0.6) on 5-point scale.
- Dose-dependent lessening of serum IL-2 release with IMU-856; citrulline levels increased in active arms while decreasing in placebo.
- Vitamin B12 increased by 45.8 pmol/L (80mg) and 74.2 pmol/L (160mg) with IMU-856 vs. 31.0 pmol/L decrease with placebo.
- No serious adverse events; two IMU-856 patients showed Q-Marsh histology improvement despite gluten challenge vs. none on placebo.